TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Dong Won | - |
dc.contributor.author | Kim, Yun Jin | - |
dc.contributor.author | Sung, Yoon Kyoung | - |
dc.contributor.author | Chung, Sung Jun | - |
dc.contributor.author | Yeo, Yoomi | - |
dc.contributor.author | Park, Tai Sun | - |
dc.contributor.author | Lee, Hyun | - |
dc.contributor.author | Moon, Ji yong | - |
dc.contributor.author | Kim, Sang Heon | - |
dc.contributor.author | Kim, Tae Hyung | - |
dc.contributor.author | Yoon, Ho Joo | - |
dc.contributor.author | Sohn, Jang Won | - |
dc.date.accessioned | 2022-07-06T08:41:11Z | - |
dc.date.available | 2022-07-06T08:41:11Z | - |
dc.date.created | 2022-04-06 | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/139327 | - |
dc.description.abstract | The aim of this study is to examine the impact of tumor necrosis factor inhibitors (TNFI) on nontuberculous mycobacterium (NTM) infection in rheumatoid arthritis (RA) patients in a mycobacterium tuberculosis (MTB) endemic area. We selected 1089 TNFI-treated RA patients and 4356 untreated RA patients using propensity-matching analysis according to age, gender, and Charlson comorbidity index using the Korean National Health Insurance Service database from July 2009 to December 2010. Both groups were followed-up until the end of 2016 to measure the incidence of mycobacterial diseases. The incidence rate of NTM in TNFI-treated RA group was similar to those of MTB (328.1 and 340.9 per 100,000 person-years, respectively). The adjusted hazard ratio (aHR) of NTM for TNFI-treated RA compared to untreated RA was 1.751(95% CI 1.105–2.774). The risk of TNFI-associated NTM in RA was 2.108-fold higher among women than men. The age-stratified effects of TNFI on NTM development were significantly high in RA patients aged 50–65 years (aHR 2.018). RA patients without comorbidities had a higher incidence of NTM following TNFI treatment (aHR 1.742). This real-world, observational study highlights the need to increase awareness of NTM in TNFI-treated RA patients in an MTB endemic area. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Nature Research | - |
dc.title | TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Dong Won | - |
dc.contributor.affiliatedAuthor | Sung, Yoon Kyoung | - |
dc.contributor.affiliatedAuthor | Park, Tai Sun | - |
dc.contributor.affiliatedAuthor | Lee, Hyun | - |
dc.contributor.affiliatedAuthor | Moon, Ji yong | - |
dc.contributor.affiliatedAuthor | Kim, Sang Heon | - |
dc.contributor.affiliatedAuthor | Kim, Tae Hyung | - |
dc.contributor.affiliatedAuthor | Yoon, Ho Joo | - |
dc.contributor.affiliatedAuthor | Sohn, Jang Won | - |
dc.identifier.doi | 10.1038/s41598-022-07968-w | - |
dc.identifier.scopusid | 2-s2.0-85126077005 | - |
dc.identifier.wosid | 000765922600096 | - |
dc.identifier.bibliographicCitation | Scientific Reports, v.12, no.1, pp.1 - 9 | - |
dc.relation.isPartOf | Scientific Reports | - |
dc.citation.title | Scientific Reports | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ANTITUMOR NECROSIS FACTOR | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | NATIONAL-HEALTH INSURANCE | - |
dc.subject.keywordPlus | FACTOR ANTAGONISTS | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | FREQUENCY | - |
dc.subject.keywordPlus | ONTARIO | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.identifier.url | https://www.nature.com/articles/s41598-022-07968-w | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.